LSV Asset Management Acquires 29,300 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

LSV Asset Management increased its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,900 shares of the life sciences company’s stock after purchasing an additional 29,300 shares during the period. LSV Asset Management owned approximately 0.31% of Integra LifeSciences worth $5,396,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Raymond James Financial Inc. bought a new position in Integra LifeSciences in the fourth quarter valued at approximately $943,000. Quadrant Capital Group LLC lifted its position in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 1,371 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Integra LifeSciences by 28.0% in the 4th quarter. Russell Investments Group Ltd. now owns 108,890 shares of the life sciences company’s stock worth $2,470,000 after purchasing an additional 23,788 shares during the period. ExodusPoint Capital Management LP bought a new position in Integra LifeSciences during the 4th quarter worth about $1,096,000. Finally, Villanova Investment Management Co LLC raised its stake in shares of Integra LifeSciences by 10.8% in the 4th quarter. Villanova Investment Management Co LLC now owns 43,224 shares of the life sciences company’s stock valued at $980,000 after purchasing an additional 4,217 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $16.99 on Monday. The firm has a market capitalization of $1.31 billion, a P/E ratio of -188.76, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The firm’s fifty day moving average price is $22.28 and its two-hundred day moving average price is $22.34. Integra LifeSciences Holdings Co. has a 1 year low of $15.95 and a 1 year high of $33.04.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the prior year, the firm earned $0.89 EPS. Integra LifeSciences’s quarterly revenue was up 11.5% compared to the same quarter last year. As a group, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.